TriangleNCT03544281 · REGISTRY CONDITION SEARCH
To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.
- Phase
- PHASE1, PHASE2
- Status at capture
- COMPLETED
- Registry last update
- 2025-03-18
This study will evaluate the safety and tolerability profile of belantamab mafodotin when administered in combination with approved regimens of either Lenalidomide Plus Dexamethasone \[Len/Dex (Treatment A)\] or Bortezomib Plus Dexamethasone \[Bor/Dex (Treatment B)\] in participants with RRMM, i.e., those who have relapsed or who are refractory to at least 1 line of approved therapy. Participants receiving treatment A, may continue combination treatment until the occurrence of progressive disease (PD), intolerable adverse events (AEs ), consent withdrawal, death or end of study. The participants receiving treatment B, may continue combination treatment for a total of up to 8 cycles. After 8 cycles of combination therapy, the participants will continue treatment with belantamab mafodotin, as a monotherapy until the occurrence of PD, intolerable AEs, consent withdrawal, death or end of study.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Participant flow
Baseline characteristics
Number of Participants With Dose Limiting Toxicities (DLTs), Treatment A
Number of Participants With DLTs, Treatment B
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Number of Participants With Worst-Case Amount of Increase From Baseline Value in Corrected QT Interval Using Fredericia's Formula (QTcF)
Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters
Number of Participants With Worst-case Change Post-baseline in Hematology Parameters
Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters
Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters
Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein
Change From Baseline in Urine Potential of Hydrogen (pH)
Change From Baseline in Urine Specific Gravity
Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)
Change From Baseline in Vital Signs : Pulse Rate
Change From Baseline in Vital Signs : Temperature
Overall Response Rate (ORR) as Defined by the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma (MM)
Maximum Observed Concentration (Cmax) for Belantamab Mafodotin Antibody-drug Conjugate (ADC), Treatment A
Area Under the Concentration Time Curve (AUC) From Time 0 to 504 Hours (0-504h) for Belantamab Mafodotin ADC, Treatment A
AUC (0-672h) for Belantamab Mafodotin ADC, Treatment A
Time to Reach Maximum Observed Concentration (Tmax) for Belantamab Mafodotin ADC, Treatment A
Time of Last Observed Quantifiable Concentration (Tlast) for Belantamab Mafodotin ADC, Treatment A
Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) for Belantamab Mafodotin ADC, Treatment A
Observed Plasma Concentration at the End of Infusion (C-EOI) for Belantamab Mafodotin ADC, Treatment A
Cmax for Belantamab Mafodotin ADC, Treatment B
AUC (0-504h) for Belantamab Mafodotin ADC, Treatment B
AUC (0-1008h) for Belantamab Mafodotin ADC, Treatment B
Tmax for Belantamab Mafodotin ADC, Treatment B
Tlast for Belantamab Mafodotin ADC, Treatment B
Ctrough for Belantamab Mafodotin ADC, Treatment B
C-EOI for Belantamab Mafodotin ADC, Treatment B
Cmax for Belantamab Mafodotin (Total Antibody), Treatment A
AUC (0-504h) for Belantamab Mafodotin (Total Antibody), Treatment A
AUC (0-672h) for Belantamab Mafodotin (Total Antibody), Treatment A
AUC (0-1008h) for Belantamab Mafodotin (Total Antibody), Treatment A
AUC(0-1344h) for Belantamab Mafodotin (Total Antibody), Treatment A
Tmax for Belantamab Mafodotin (Total Antibody), Treatment A
Tlast for Belantamab Mafodotin (Total Antibody), Treatment A
Ctrough for Belantamab Mafodotin (Total Antibody), Treatment A
C-EOI for Belantamab Mafodotin (Total Antibody), Treatment A
Cmax for Belantamab Mafodotin (Total Antibody) Treatment B
AUC (0-504h) for Belantamab Mafodotin (Total Antibody), Treatment B
AUC (0-1008h) for Belantamab Mafodotin (Total Antibody), Treatment B
Tmax for Belantamab Mafodotin (Total Antibody), Treatment B
Tlast for Belantamab Mafodotin (Total Antibody), Treatment B
Ctrough for Belantamab Mafodotin (Total Antibody), Treatment B
C-EOI for Belantamab Mafodotin (Total Antibody), Treatment B
Cmax for Belantamab Mafodotin Cysteine Maleimidocaproyl Monomethyl Auristatin F (Cys-mcMMAF), Treatment A
AUC (0-168h) for Belantamab Mafodotin (Cys-mcMMAF), Treatment A
AUC (0-336h) for Belantamab Mafodotin (Cys-mcMMAF), Treatment A
Tmax for Belantamab Mafodotin (Cys-mcMMAF), Treatment A
Tlast for Belantamab Mafodotin (Cys-mcMMAF), Treatment A
C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment A
Cmax for Belantamab Mafodotin (Cys-mcMMAF) Treatment B
AUC(0-168h) for Belantamab Mafodotin (Cys-mcMMAF), Treatment B
Tmax for Belantamab Mafodotin (Cys-mcMMAF), Treatment B
Tlast for Belantamab Mafodotin (Cys-mcMMAF), Treatment B
C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment B
Cmax for Lenalidomide (25 mg), Treatment A
AUC(0-24h) for Lenalidomide (25 mg), Treatment A
AUC (0-4h) for Lenalidomide (25 mg), Treatment A
Tmax for Lenalidomide (25 mg), Treatment A
Tlast for Lenalidomide (25 mg), Treatment A
Cmax for Lenalidomide (10 mg), Treatment A
AUC(0-24h) for Lenalidomide (10 mg), Treatment A
AUC (0-4h) for Lenalidomide (10 mg), Treatment A
Tmax for Lenalidomide (10 mg), Treatment A
Tlast for Lenalidomide (10 mg), Treatment A
Cmax for Bortezomib, Treatment B
AUC (0-72h) for Bortezomib, Treatment B
AUC (0-t) for Bortezomib, Treatment B
Tmax for Bortezomib, Treatment B
Tlast for Bortezomib, Treatment B
Number of Participants With Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin
Titers of ADAs Against Belantamab Mafodotin
Change From Baseline in Ocular Surface Disease Index (OSDI) Total Scores
Change From Baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) Overall Composite Scores
Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Number of Participants With AEs of Special Interest (AESI)
Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores
Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results
Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception
Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline)
Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score
Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score
Adverse events
Limitations, agreements, and source contact
Who could take part
- eligibility Criteria
- Inclusion Criteria: * Capable of giving signed informed consent. * Male or female, 18 years or older (at the time consent is obtained). * Have confirmed diagnosis of Multiple Myeloma (MM) as defined by the IMWG. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 for Arm A and 0 to 2 for Arm B. * Have undergone stem cell transplant (SCT), or are considered transplant ineligible. * Have been previously treated with at least 1 prior line of MM therapy, and must have documented disease progression during or after their most recent therapy. * Must have at least ONE aspect of measurable disease, defined as one the following: Urine M-protein excretion \>=200 milligram (mg)/24 hours, or; Serum M-protein concentration \>=0.5 gram (g)/deciliter (dL) (\>=5.0 g/Liter), or; Serum free light chain (FLC) assay: involved FLC level \>=10 mg/dL (\>=100 mg/L) and an abnormal serum FLC ratio (\<0.26 or \>1.65). * Participants with a history of autologous SCT, are eligible for study participation provided the following eligibility criteria are met: Autologous SCT was \>100 days prior to study enrollment; No active bacterial, viral, or fungal infection(s) present; Participant meets the remainder of the eligibility criteria. * All prior treatment-related toxicities (defined by National Cancer Institute Common Toxicity Criteria for Adverse Events \[NCI-CTCAE\], Version 4.03, 2010) must be Grade \<= 1 at the time of enrollment, except for alopecia. Participants with Grade 2 neuropathy can be enrolled into Len/Dex treatment arm, but not into Bor/Dex treatment arm. * Adequate organ system functions as defined by the laboratory assessments. * The contraceptions used by female participants be consistent with local regulations, regarding methods of contraception for those participating in clinical studies. A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: is not a woman of child bearing potential (WOCBP) or Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of \<1% per year), preferably with low user dependency, during the intervention period and for at least 4 months after the last dose of belantamab mafodotin and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy. WOCBP Participants Assigned to Arm A: * Due to lenalidomide being a thalidomide analogue with risk for embryo-fetal toxicity and prescribed under a pregnancy prevention/controlled distribution program, WOCBP participants will be eligible if they commit either to abstain continuously from heterosexual sexual intercourse or to use two methods of reliable birth control (one method that is highly effective; beginning 4 weeks prior to initiating treatment with lenalidomide, during therapy, during dose interruptions and continuing for 4 weeks following discontinuation of lenalidomide treatment. Thereafter, WOCBP participants must use a contraceptive method that is highly effective (with a failure rate of \<1% per year) for a further 3 months, and agree not to donate eggs (ova, oocytes) for the purpose of reproduction during this period: Two negative pregnancy tests must be obtained prior to initiating lenalidomide therapy. The first test should be performed within 10-14 days and the second test within 24 hours prior to prescribing lenalidomide therapy. WOCBP Participants Assigned to Arm B * WOCBP assigned to Arm B must have a negative highly sensitive serum pregnancy test within 72 hours of dosing on C1D1 and agree to use effective contraception during the study and for 4 months after the last dose of belantamab mafodotin or 7 months from the last dose of bortezomib, whichever is longer. * Male participants using contraception should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. * Male participants are eligible to participate if they agree to the following: Arm A: from the time of first dose of study until 6 months after the last dose of belantamab mafodotin 4 weeks after the last dose of lenalidomide, whichever is longer, to allow for clearance of any altered sperm. Arm B: from the time of first dose of study until 6 months after the last dose of belantamab mafodotin or 4 months from the last dose of bortezomib (whichever is the longer) to allow for clearance of any altered sperm. * Male participants must agree to refrain from donating sperm and either be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent OR Must agree to use contraception/barrier as detailed below. * Agree to use a male condom even if they have undergone a successful vasectomy and female partner to use an additional highly effective contraceptive method with a failure rate of \<1% per year when having sexual intercourse. Male participants should also use a condom with pregnant females. If the female partner of the male participant is pregnant at the time of enrollment, or becomes pregnant during the trial, the male participant must agree to remain abstinent (if it is consistent with their preferred and usual lifestyle) or use a male condom. Exclusion Criteria: * Systemic anti-myeloma therapy (including systemic steroids) within \<=14 days, or plasmapheresis within 7 days prior to the first dose of study drug. * Use of an investigational drug within 14 days or five half-lives (whichever is longer) preceding the first dose of study drug. * Prior treatment with a monoclonal antibody within 30 days of receiving the first dose of study drugs. * Prior allogenic stem cell transplant. Note: Participants who have undergone syngeneic transplant will be allowed only if they have no history and no currently active, graft versus host disease (GvHD). * Evidence of active mucosal or internal bleeding. * Any major surgery within the last four weeks. * Presence of active renal condition (infection, requirement for dialysis or any other condition that could affect participant's safety). Participants with isolated proteinuria resulting from MM are eligible, provided they fulfill criteria. * Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions (including lab abnormalities) that could interfere with participant's safety, obtaining informed consent or compliance to the study procedures. * Current active liver or biliary disease (with the exception of Gilbert's syndrome or asymptomatic gallstones, or otherwise stable chronic liver disease per investigator's assessment). * Participants with invasive malignancies other than multiple myeloma are excluded, unless the second malignancy has been considered medically stable for at least 2 years. The participant must not be receiving active therapy, other than hormonal therapy for this disease. Note: Participants with curatively treated non-melanoma skin cancer are allowed without a 2-year restriction. * Evidence of cardiovascular risk including any of the following: Evidence of current clinically significant uncontrolled arrhythmias, including clinically significant ECG abnormalities including 2nd degree (Type II) or 3rd degree atrioventricular (AV) block; History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting within 3 months of Screening; Class III or IV heart failure as defined by the New York Heart Association functional classification system; Uncontrolled hypertension. * Known immediate or delayed hypersensitivity reaction or idiosyncratic reaction to drugs chemically related to belantamab mafodotin, or any of the components of the study treatment. * Pregnant or lactating female. * Active infection requiring treatment. * Known Human immunodeficiency virus (HIV) infection. * Presence of hepatitis B surface antigen (HBsAg), or hepatitis B core antibody (HBcAb at Screening or within 3 months prior to first dose of study treatment). * Current corneal disease except for mild punctuate keratopathy. * Positive hepatitis C antibody test result or positive hepatitis C Ribonucleic acid (RNA) test result at Screening or within 3 months prior to first dose of study treatment. * Current corneal disease except for mild punctute keratopathy. * Participants Assigned to Treatment A (belantamab mafodotin plus Len/Dex): Participants unable to tolerate antithrombotic prophylaxis must be excluded; Discontinuation of prior treatment with lenalidomide due to intolerable AEs. * Participants Assigned to Treatment B (belantamab mafodotin plus Bor/Dex): Unacceptable AEs from previous bortezomib treatment; Ongoing Grade 2 or higher peripheral neuropathy or neuropathic pain from previous bortezomib treatment; Intolerance or contraindications to anti-viral prophylaxis.
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- description
- Participants will receive SINGLE full dose of belantamab mafodotin as 2.5 mg/kg and 1.9 mg/kg on Day 1 of every 28-day cycle as a 30-60 min infusion. SPLIT: belantamab mafodotin will be administered in two equal divided doses, 2.5 mg/kg SPLIT dose of a 1.25 mg/kg dose on Day 1 and a 1.25 mg/kg dose on Day 8 of each 28-day cycle. STRETCH: belantamab mafodotin will be administered as 1.9 mg/kg dose on Day 1 of every alternate 28-day cycles (C1, C3, C5, C7 and so on.) Participants will also receive Lenalidomide 25 mg or 10 mg orally daily, on Days 1-21 of each 28 day cycle with Dexamethasone, 40 mg weekly per oral (PO)/intravenously (IV) on Days 1,8,15, \& 22 of each cycle.
- intervention Names
- Drug: Belantamab mafodotin
- Drug: Lenalidomide
- Drug: Dexamethasone
- label
- Arm A: Belantamab mafodotin+lenalidomide +dexamethasone
- type
- EXPERIMENTAL
- description
- Participants will receive SINGLE full dose of belantamab mafodotin as 3.4 mg/kg; 2.5 mg/kg; 1.9 mg/kg on Day 1 of each 21-day cycle. SPLIT: belantamab mafodotin will be administered in two equal divided doses: 3.4 mg/kg SPLIT as 1.7 mg/kg dose on Day 1 \& 1.7 mg/kg dose on Day 8; 2.5 mg/kg SPLIT dosing as 1.25 mg/kg dose on Day 1 \& 1.25 mg/kg dose on Day 8 of each 21-day cycle. STRETCH: belantamab mafodotin will be administered as single dose of 2.5 mg/kg on Day 1 of every alternate 21-day cycles (C1,C3,C5,C7 \& so on), 1.9 mg/kg administered on Day 1 of every alternate 21-day cycles (C1,C3,C5,C7 and so on). Step Down(S/D) STRETCH=belantamab mafodotin 2.5 mg/kg dose will be administered on Day 1 C1 followed by 1.9 mg/kg starting dose on Day1 of alternate 21-day cycles C3 onwards (C3,C5,C7, \& so on). Bortezomib will be administered at 1.3 mg/m\^2 SC/IV on Days 1,4,8, \& 11 of every 21-day cycle. Dex will be administered at 20 mg PO or IV on Days 1,2,4,5,8,9,11, \& 12 of every 21-day cycle.
- intervention Names
- Drug: Belantamab mafodotin
- Drug: Dexamethasone
- Drug: Bortezomib
- label
- Arm B: Belantamab mafodotin+bortezomib+dexamethasone
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- Arm A: Belantamab mafodotin+lenalidomide +dexamethasone
- Arm B: Belantamab mafodotin+bortezomib+dexamethasone
- description
- Selected doses of belantamab mafodotin will be administered as an infusion.
- name
- Belantamab mafodotin
- type
- DRUG
- arm Group Labels
- Arm A: Belantamab mafodotin+lenalidomide +dexamethasone
- description
- Lenalidomide will be administered as 25 or 10 mg,orally, with belantamab mafodotin and dexamethasone.
- name
- Lenalidomide
- type
- DRUG
- arm Group Labels
- Arm A: Belantamab mafodotin+lenalidomide +dexamethasone
- Arm B: Belantamab mafodotin+bortezomib+dexamethasone
- description
- Dexamethasone will be administered as 20 or 40 mg, orally with belantamab mafodotin.
- name
- Dexamethasone
- type
- DRUG
- arm Group Labels
- Arm B: Belantamab mafodotin+bortezomib+dexamethasone
- description
- Bortezomib will be administered as 1.3 mg/m\^2, as SC or IV, with belantamab mafodotin and dexamethasone.
- name
- Bortezomib
- type
- DRUG
Study design
- allocation
- NON_RANDOMIZED
- intervention Model
- SEQUENTIAL
- masking Info
- masking
- NONE
- masking Description
- This is an open-label study; therefore, no blinding of treatment identity will be done for both treatments.
- primary Purpose
- TREATMENT
Enrollment
- count
- 153
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- DLT is an adverse event (AE) that is considered by the investigator to be clinically relevant and attributed to the study therapy during the 28 day DLT period and meets at least one of the DLT criteria: Grade 3 or greater febrile neutropenia lasting \>48 hours (h) despite adequate treatment; Grade 4 thrombocytopenia \<25,000/mm\^3 accompanied by significant bleeding; any Grade 3 or greater non-hematologic laboratory value (if laboratory abnormality persist \>48 h despite supportive treatment or abnormality leading to hospitalisation); non-hematologic toxicity which does not resolve with appropriate supportive treatment within 48 h, Grade 4 corneal adverse events; and other organ specific toxicities (liver toxicity that causes discontinuation of treatment).
- measure
- Number of Participants With Dose Limiting Toxicities (DLTs), Treatment A
- time Frame
- Up to 28 days
- description
- DLT is an adverse event (AE) that is considered by the investigator to be clinically relevant and attributed to the study therapy during the 21 day DLT period and meets at least one of the DLT criteria: Grade 3 or greater febrile neutropenia lasting \>48 hours (h) despite adequate treatment; Grade 4 thrombocytopenia \<25,000/mm\^3 accompanied by significant bleeding; any Grade 3 or greater non-hematologic laboratory value (if laboratory abnormality persist \>48 h despite supportive treatment or abnormality leading to hospitalisation); non-hematologic toxicity which does not resolve with appropriate supportive treatment within 48 h, Grade 4 corneal adverse events; and other organ specific toxicities (liver toxicity that causes discontinuation of treatment).
- measure
- Number of Participants With DLTs, Treatment B
- time Frame
- Up to 21 days
- description
- An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, Is life-threatening, Requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent disability/incapacity or Is a congenital anomaly/birth defect, Other situations which involve medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. A summary of number of participants with any AEs and SAEs are presented. AEs were coded using the Medical Dictionary for Regulatory Affairs (MedDRA dictionary).
- measure
- Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
- time Frame
- Up to approximately 4.5 years
- description
- 12-lead electrocardiogram (ECGs) were obtained using an automated ECG machine that automatically calculated the QTcF intervals. QTc values are categorized into the clinical concern ranges which are specific to changes in QTc: 31-60 milliseconds (msec), and \>60 msec, and \>530msec. An increase is defined relative to Baseline. Baseline (Day 1) was defined as latest pre-dose assessment with non-missing value, including unscheduled visits. Data of number of participants with worst-case increase post baseline is presented.
- measure
- Number of Participants With Worst-Case Amount of Increase From Baseline Value in Corrected QT Interval Using Fredericia's Formula (QTcF)
- time Frame
- Up to approximately 4.5 years
- description
- Blood samples were collected for analysis of following hematology parameters: Hemoglobin (hemoglobin increased and anemia), Lymphocytes (lymphocyte count increased and lymphocyte count decreased), Neutrophils, Platelets and Leukocytes (leukocytosis and white blood cells decreased). The laboratory parameters were graded according to Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4.03. Grade (G) 1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with non-missing value, including unscheduled visits. Any worst-case post baseline increases in grade along with any increase to a maximum G3 and a maximum G4 are presented.
- measure
- Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters
- time Frame
- Baseline (Day 1) and up to approximately 4.5 years
- description
- Blood samples were collected for the analysis of following hematology parameters: basophils, eosinophils, hematocrit, mean corpuscular hemoglobin concentration (MCHC), mean corpuscular hemoglobin (MCH), mean corpuscular volume (MCV), monocytes, erythrocytes and reticulocyte. The summaries of worst-case change from baseline with respect to normal range was analyzed for only those laboratory tests that were not gradable by CTCAE version 4.03. The number of participants with decreases to low from baseline, changes to normal or no changes from baseline, and increases to high values from baseline have been presented. Baseline (Day 1) was defined as latest pre-dose assessment with non-missing value, including unscheduled visits.
- measure
- Number of Participants With Worst-case Change Post-baseline in Hematology Parameters
- time Frame
- Baseline (Day 1) and up to approximately 4.5 years
- description
- Blood samples were collected for analysis of following clinical chemistry parameters: Hyperglycemia, Hypoglycemia, Albumin, Alkaline Phosphatase, Alanine Aminotransferase (ALT), Aspartate Aminotransferase, (AST), Bilirubin, Creatine Kinase (CK), Creatinine, Gamma Glutamyl Transferase (GGT), Hyperkalemia, Hypokalemia, Hypermagnesemia, Hypomagnesemia, Phosphate, Hypernatremia, Hyponatremia, Urate, Hypercalcemia and Hypocalcemia. Laboratory parameters were graded according to CTCAE v4.03. Grade (G) 1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with non-missing value, including unscheduled visits. Any worst-case post baseline increases in grade along with any increase to a maximum G3 and a maximum G4 are presented.
- measure
- Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters
- time Frame
- Baseline (Day 1) and up to approximately 4.5 years
- description
- Blood samples were collected for analysis of following clinical chemistry parameters: Direct Bilirubin (DB), Calcium, Chloride, Carbon Dioxide (CO2), lactate dehydrogenase (LDH) and Protein. The summaries of worst-case change from baseline with respect to normal range was analyzed for only those laboratory tests that were not gradable by CTCAE version 4.03. The number of participants with decreases to low from baseline, changes to normal or no changes from baseline, and increases to high values from baseline have been presented. Baseline (Day 1) was defined as latest pre-dose assessment with non-missing value, including unscheduled visits.
- measure
- Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters
- time Frame
- Baseline (Day 1) and up to approximately 4.5 years
- description
- Urine samples were collected to analyze presence of occult blood and protein in urine by dipstick method. Data for worst-case post baseline urinalysis results is presented. Result for urinalysis parameters were recorded as no change/decreased and increase to trace, 1+, 2+, 3+, \>3+ indicating proportional concentrations in the urine sample. Baseline (Day 1) was defined as latest pre-dose assessment with non-missing value, including unscheduled visits.
- measure
- Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein
- time Frame
- Baseline (Day 1) and up to approximately 4.5 years
- description
- Urine samples were collected to analyze urine pH levels. Baseline (Day 1) was defined as latest pre-dose assessment with non-missing value, including unscheduled visits.
- measure
- Change From Baseline in Urine Potential of Hydrogen (pH)
- time Frame
- Baseline (Day 1) and up to approximately 4.5 years
- description
- Urine samples were collected to analyze urine specific gravity using dipstick method. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits.
- measure
- Change From Baseline in Urine Specific Gravity
- time Frame
- Baseline (Day 1) and up to approximately 4.5 years
- description
- Blood pressures (DBP and SBP) were measured after resting for at least 5 minutes in a supine or semi-recumbent position. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated as post-dose visit value minus Baseline value.
- measure
- Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)
- time Frame
- Baseline (Day 1) and up to approximately 4.5 years
- secondary Outcomes
- description
- Blood samples were collected at indicated timepoints for pharmacokinetic (PK) analysis. PK parameter was determined using standard non-compartmental methods.
- measure
- Maximum Observed Concentration (Cmax) for Belantamab Mafodotin Antibody-drug Conjugate (ADC), Treatment A
- time Frame
- Pre-Dose, 0, 2 and 24 hours post-dose on Cycle 1 Day 1 and Cycle 1 Day 8
- description
- Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods.
- measure
- Area Under the Concentration Time Curve (AUC) From Time 0 to 504 Hours (0-504h) for Belantamab Mafodotin ADC, Treatment A
- time Frame
- Pre-Dose, 0, 2 and 24 Hours Post-Dose on Cycle 1 Day 1; Cycle 1 Day 4; Cycle 1 Day 8; Cycle 1 Day 11; Cycle 1 Day 15-21
- description
- Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods.
- measure
- AUC (0-672h) for Belantamab Mafodotin ADC, Treatment A
- time Frame
- Pre-Dose, 0, 2 and 24 Hours Post-Dose on Cycle 1 Day 1; Cycle 1 Day 4; Cycle 1 Day 8; Cycle 1 Day 11; Cycle 1 Day 15-21; Cycle 1 Day 28
- description
- Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods.
- measure
- Time to Reach Maximum Observed Concentration (Tmax) for Belantamab Mafodotin ADC, Treatment A
- time Frame
- Pre-Dose, 0, 2 and 24 Hours Post-Dose on Cycle 1 Day 1 and Cycle 1 Day 8
- description
- Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods. Tlast is the time of last observed quantifiable concentration of belantamab mafodotin in Cycle 1 which extended beyond protocol defined duration for some participants across treatment groups.
- measure
- Time of Last Observed Quantifiable Concentration (Tlast) for Belantamab Mafodotin ADC, Treatment A
- time Frame
- Pre-Dose, 0, 2 and 24 Hours Post-Dose on Cycle 1 Day 1 and Cycle 1 Day 4; Cycle 1 Day 8; Cycle 1 Day 11; Cycle 1 Day 15-21; Cycle 1 Day 29; pre-dose Cycle 2 Day 28
- description
- Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods.
- measure
- Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) for Belantamab Mafodotin ADC, Treatment A
- time Frame
- Cycle 1: Pre-Dose, 0, 2 and 24 Hours Post-Dose on Days 1 and 8; Weeks 5, 9, and 13: Pre-Dose and Post-Dose on Days 1 and 8
- description
- Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods.
- measure
- Observed Plasma Concentration at the End of Infusion (C-EOI) for Belantamab Mafodotin ADC, Treatment A
- time Frame
- Cycle 1: Pre-Dose, 0, 2 and 24 Hours Post-Dose on Days 1 and Day 8; Weeks 5, 9, and 13: Pre-Dose and Post-Dose on Days 1 and 8
- description
- Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods.
- measure
- Cmax for Belantamab Mafodotin ADC, Treatment B
- time Frame
- Pre-Dose, 0, 2 and 24 Hours Post-Dose on Cycle 1 Day 1 and Cycle 1 Day 8
- description
- Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods.
- measure
- AUC (0-504h) for Belantamab Mafodotin ADC, Treatment B
- time Frame
- Pre-Dose, 0, 2 and 24 Hours Post Dose on Cycle 1 Day 1; Cycle 1 Day 4; Cycle 1 Day 8; Cycle 1 Day 11; Cycle 1 Day 21
- description
- Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods. AUC(0-1008h) was derived only for Belantamab mafodotin 1.9 mg/kg STRETCH + Bor/Dex, Belantamab mafodotin 2.5 mg/kg StepDown STRETCH + Bor/Dex and Belantamab mafodotin 2.5 mg/kg STRETCH + Bor/Dex cohorts.
- measure
- AUC (0-1008h) for Belantamab Mafodotin ADC, Treatment B
- time Frame
- Pre-Dose, 0, 2 and 24 Hours Post Dose on Cycle 1 Day 1; Cycle 1 Day 4; Cycle 1 Day 11; Cycle 1 Day 22; Pre-Dose and Post-Dose on Week 5 Day 7
- description
- Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods.
- measure
- Tmax for Belantamab Mafodotin ADC, Treatment B
- time Frame
- Pre-Dose, 0, 2 and 24 Hours Post-Dose on Cycle 1 Day 1 and Cycle 1 Day 8
- description
- Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods. Tlast is the time of last observed quantifiable concentration of belantamab mafodotin in Cycle 1 which extended beyond protocol defined duration for some participants across treatment groups.
- measure
- Tlast for Belantamab Mafodotin ADC, Treatment B
- time Frame
- Pre-Dose Cycle 1 Day 1 to pre-dose Cycle 5 Day 1
Full study description
- brief Summary
- This study will evaluate the safety and tolerability profile of belantamab mafodotin when administered in combination with approved regimens of either Lenalidomide Plus Dexamethasone \[Len/Dex (Treatment A)\] or Bortezomib Plus Dexamethasone \[Bor/Dex (Treatment B)\] in participants with RRMM, i.e., those who have relapsed or who are refractory to at least 1 line of approved therapy. Participants receiving treatment A, may continue combination treatment until the occurrence of progressive disease (PD), intolerable adverse events (AEs ), consent withdrawal, death or end of study. The participants receiving treatment B, may continue combination treatment for a total of up to 8 cycles. After 8 cycles of combination therapy, the participants will continue treatment with belantamab mafodotin, as a monotherapy until the occurrence of PD, intolerable AEs, consent withdrawal, death or end of study.
Source references
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-1336d216cbd1bbff780dac70
- edge id
- nct-edge-bd5e261dcf6db923ccbe
- requested nct id
- NCT03544281
- primary nct id
- NCT03544281
- source kind
- ctgov_condition_query
- source record id
- Source null
- source file sha256
- 2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
- payload sha256
- 78f315d2710a71ff1635bb3c3af15a8189ba16e69229c2356d61f89e20013d38
- payload
- clinical indication matching status
- condition_index_match_asserted_by_registry_not_reviewed
- end exclusive
- true
- id
- nct-edge-bd5e261dcf6db923ccbe
- link basis
- returned_by_explicit_condition_and_posted_results_filter_query
- nct id
- NCT03544281
- occurrences
- context exact
- NCT03544281
- end
- 11
- exact text
- NCT03544281
- start
- 0
- offset unit
- unicode_code_points
- query cond
- Plasma Cell Neoplasms
- query disease state id
- ds-plasma-cell-neoplasms
- source file
- /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
- source file sha256
- 2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
- source json pointer
- /studies/353/protocolSection/identificationModule/nctId
- source kind
- ctgov_condition_query
- source record id
- Source null
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- d2b94737627a97de4bfabf58a2f04aae7722578e2e9c65a48988450a76f1a542
Preserved source evidence · Not medical advice